ALAMEDA, Calif. , Oct. 30, 2024 /PRNewswire/ -- Penumbra, Inc.
(NYSE: PEN ), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2024 . Revenue of $301.0 million in the third quarter of 2024, an increase of 11.
1% or 10.9% in constant currency 1 , compared to the third quarter of 2023. U.
S. thrombectomy revenue of $162.1 million in the third quarter of 2024 increased 21.
2% and 5.4% compared to the third quarter of 2023 and second quarter of 2024, respectively, led by growth in our U.S.
VTE franchise, which grew 32% compared to the third quarter of 2023. Income from operations of $35.4 million and Non-GAAP income from operations 1 of $40.
3 million in the third quarter of 2024. Net income of $29.5 million and adjusted EBITDA 1 of $56.
7 million or net income margin of 9.8% and adjusted EBITDA margin of 18.8% in the third quarter of 2024.
Third Quarter 2024 Financial Results Total revenue increased to $301 .0 million for the third quarter of 2024 compared to $270 .9 million for the third quarter of 2023, an increase of 11.
1%, or 10.9% in constant currency 1 . The United States represented 75.
2% of total revenue and international represented 24.8% of total revenue for the third quarter of 2024. Revenue from the U.
S. increased 16.2% while revenue from our international regions decreased 1.
9%, or 2.5% in constant currency 1 . Revenue from sales of our global thrombectomy products grew to $204 .
1 million in the third qua.